Transcript
Speaker: Welcome to Critical Matters, a sound podcast covering a broad range of topics related to the practice of intensive care medicine. Sound provides comprehensive critical care programs to hospitals across the country.
Speaker: To learn more about our programs and career opportunities, visit www.soundphysicians.com. And now your host, Dr. Sergio Zanotti.
Speaker: Heparin-induced thrombocytopenia presents a unique challenge in patients who undergo cardiac surgery. In this population, factors such as universal preoperative exposure to heparin products, postoperative heparin platelets kinetics, and specific therapeutic needs affect HIT diagnosis and management.
Speaker: To address these challenges, the American Association of Thoracic Surgery recently published an expert consensus document. We will discuss this topic using the expert consensus document as our roadmap.
Speaker: We are honored and very grateful to have two of the authors of this important clinical guideline on the podcast today. Dr. Subhasis Chatterjee, a cardiothoracic surgeon and critical care physician from the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, from the Department of Cardiovascular Surgery at the Texas Heart Institute, Baylor College of Medicine in Houston, Texas, and Dr. Daniel Engelman, a cardiothoracic surgeon and critical care physician from the Department of Surgery at Bay State Medical Center, University of Massachusetts Chan Medical School in Bay State Springfield, Massachusetts.
Speaker: Shuba and Dan, thank you for being on the podcast and welcome to Critical Matters. So I would like to start with Daniel. Why should our listeners care about this topic?
Speaker: Well, great question. It turns out Cardiac surgeons have a lot of problems when it comes to heparin-induced thrombocytopenia because the use of heparin in our population is ubiquitous. So every cardiac surgery patient receives heparin at the time of cardiac surgery. They get a full dose while they're on cardiopulmonary bypass. But in addition, most or many have had it before heparin.
Speaker: entering the operating room, anyone who came in with an acute coronary syndrome or any patient that went to the cardiac catheterization lab, which is probably 90 to 95% of our patients at the time of cardiac catheterization received some heparin. So now you have a preoperative heparin exposure,
Speaker: a large second heparin exposure when you get to the operating room. And then the third major problem for our patient population is that almost all of them get thrombocytopenic when they're in the operating room due to the cardiopulmonary bypass pump, dilution, hemorrhage, loss of blood, et cetera. And this count can drop on average 40 to 50% after bypass. So now you have heparin exposure, thrombocytopenia,
Speaker: And you have no idea who has heparin-induced thrombocytopenia, which can also have the sequela of thrombosis. And in addition, it's even worse than that. Because if you check antibodies in this patient, a significant number of these, about half of them, seroconvert and have antibodies after cardiopulmonary bypass. But what's fascinating is only a small minority of those platelet-activating antibodies actually are real and have any clinical consequence. So you have zero conversion, but you don't actually have hit. So we have tons of false positives when we send the wrong tests. We have tons of exposure.
Speaker: And we have all these signals of chrombocytopenia. And it's a complete mess trying to figure out who we're supposed to treat, who we should worry about, how do we test them. And even worse than that is the standard of care right now is based on the ASH guidelines, the American Society of Hematology, which wrote an outstanding guideline for all of medicine, but it was not specific to our special patient population. Shuba, jump in. What am I missing?
Speaker: So Dan, i think um I think those are really good points. um This is a common, it's an uncommon problem. Maybe two to 3% of all patients who have cardiac surgery experience it But as you outlined, it's a devastating problem. You know, it's 15 to 20% mortality, even higher if there's thrombosis associated with it. So clearly a um ah source of dismay, as well as, you know, their medical legal implications. So there's all sorts of, you know, consequences.
Speaker: Excellent. Dan, could you provide an overview of the expert consensus document in terms of goals, methods, and the and the basic structure? Yeah, so um this was a expert consensus document that was commissioned by the American Association of Thoracic Surgeons. So they have a clinical practice standards committee that picked this one topic for the year following the joint methodology of the STS and AATS and the European EAC. So it's a standard form clinical practice guideline committee expert consensus document. And what they gave us the liberty of doing was picking the multidisciplinary panel, which was actually 17 different people we put on this panel as a mixture of cardiac surgeons, intensivists, anesthesiologists, perfusionists, pharmacists. But most importantly, we picked patients.
Speaker: two hematologists that actually wrote the ASH guidelines, which included Dr. Moore Canton, who actually came up with and invented the Portis score. So we have Adam Sucre, who's the lead author of the ASH guidelines. So we we basically have...
Speaker: A document which is vetted by the hematology community. So we're not just a bunch of cardiac surgeons trying to write about a hematology topic. We've framed the hematology topic in our world that we live in, which is perioperative cardiac surgery.
Speaker: One of the things I would like to clarify before we dive into the recommendations and the actual clinical and management is the terminology. So everybody's on the same page in terms of the phases of HIT for this patient population.
Speaker: Could you go over those for us? happy to jump in. Yeah. Who do you want to address those? Go ahead, Daniel. Yeah. All right, so you have suspected hit. So you have new thrombocytopenia. We talked about that. Pretty much everybody after cardiac surgery has has some degree of thrombocytopenia plus the recent heparin exposure. So now you're thinking, what are my tools? How do I do it? Do I do a 4T score? Do I send an antibody test? Do I send a functional test? So...
Speaker: It was pretty non-standardized after cardiac surgery. That was the first time. Then you have acute hit, which is a platelet fall of 50% or more from peak, which ah usually occurs five to 10 days after heparin exposure. Mind you, that heparin exposure could have been on the cardiac catheterization lab before cardiac surgery.
Speaker: Um... that's the one that has the highest thrombosis risk and this is the phase where really nobody gets heparin then you have subacute hit and that's the place the the platelets recover And the immunoassay and the functional assays stay positive, and then you get this platelet-activating antibody that persists, and so there is a thrombosis risk.
Speaker: And then you have subacute, a different kind where um it's called subacute type D, where the functional assay is now negative. That's a little bit different.
Speaker: um And that one has much less risk of recurrence. And then you have remote hip. So the platelets recovered, Assays are negative, but the patient once had hit on the chart. So we're like, well what do we do with that? We know they had hit, you know, when they were hospitalized years ago, but now is it safe to give them Heparin again? So these are all the different kinds of hits that we tried to address.
Speaker: the The document is structured along five areas of management, which are natural history, diagnosis, treatment, need for cardiac surgery, and ECMO and MCS. So what I would like to do is to dive into each one of these and to hear a little bit of the main recommendations and the most practical aspects of caring for these patients at the bedside.
Speaker: And Dan, we'll continue with you on the natural history. You did mention a little bit about platycinetics, postcardiac surgery. Could you just review that and tell us why it's so important for HIT? So it's it's really important to remember that you expect 25% to 50% decline in the first, I would say, two to three days.
Speaker: after cardiac surgery, and that's from hemodilution. We give tons of fluid um on pump and in the perioperative timeframe. There's consumption of your platelets. There's platelet activation. And there's that mechanical destruction, which you see on cardiopulmonary bypass. And you also see it when you have mechanical circulatory support devices, such as balloon pumps and ECMO, impellas, et cetera. This is not ah immune mediated and it should recover by post-op day five so here's a takehome message i'm trying to point out the take-home messages that our listeners really should listen to. Expect a 25 to 50 percent decline in the first two to three days and expect some degree of recovery by post-op day number of five. When you don't see that recovery, that's when you should start getting you know more concerned that you might have heparin-induced thrombocytopenia. And then there's these two patterns that make you think of hits. The biphaic pattern is a take homeme point biphasic pattern, initial fall partial or full recovery of the platelet count, and then a second unexpected fall beginning on or after day five.
Speaker: Second fall beginning on or after day five. That's important. That makes you think, wow, could this be hepatotidus thrombocytopenia and then possibly thrombosis. Then on um a rarer side, sometimes we see this early persistent pattern.
Speaker: The counts fall and then they stay below 100. That's difficult because you're you really, it's less likely and you don't exactly know when to send the antibody test, but we're going to go all over that, you know, in a little bit.
Speaker: Should we check platelets every day after cardiac surgery?
Speaker: So in our document, we suggested that you should do a daily platelet count monitoring while you're hospitalized after cardiac surgery. And the reason for that was that the platelet trajectory is the earliest and often the only signal.
Speaker: You can't see a biphasic pattern if you're not drawing the counts after the patient leaves the ICU. So you have to have that daily point on the graft in order to look out for that biphasic fall. um And this also applies to patients who did not get postoperative heparin because remember the single intraoperative exposure is enough.
Speaker: And that delayed onset hit can begin five to 10 days later. So you just got a big bolus in the operating room, no heparin. You still need to follow that daily platelet count.
Speaker: Perfect. Shubha, I would like to start talking about diagnosis. And if you could explain to us or wrap all together, how does the timing in terms of post-op days and or exposure to heparin impact your diagnostic approach to HIT? Also, the 4TS score was mentioned, which is commonly utilized in medical patients. How do we integrate all this into our cardiac surgery patients?
Speaker: Sure, that's ah that's a very good point, Sergio. So you're right. So as far as platelet monitoring, the um first tool that we look at is the 4T score. And so the 4T score assigns, as is well known, whether it's thrombocytopenia, the timing in relation to that, whether there's the presence of thrombosis or other causes for this. And so this is a validated score. Actually, doctor Dr. War Kenton has previously mentioned developed the 4T scores. This is a validated scoring system.
Speaker: However, what we what is very clear as well is that the 4T score in the first ah four days after cardiac surgery is notoriously unreliable. something on the order of about 60 to 60, 60 to 70% accuracy. So in the first four days, the 4T score should not be used to guide therapy, to be able to guide this. Now, that means that you should be, if you see a severe degree of thrombocytopenia early, say day two or day three, what you should do is look back, look back at the preoperative phase and try to identify if there was a case of um heparin exposure from the cardiac cath, from some other alternative exposure that works its way so that from a timing standpoint, it could be related to that. But that is typically detected by both thrombocytopenia and obvious thrombosis, in which case you would proceed towards anticoagulation. But the important point here is that at a diagnostic level, for somebody who comes in for cardiac surgery, as Dan mentioned, expect the routine thrombocytopenia, the dilutional thrombocytopenia for three to four days, and then a bounce back in recovery and do not use the 4T score in this study.
Speaker: As you move forward, and incorporating the 4T score will be fine. Could you add? Yes. Okay, perfect. So just to make sure that we're clear, right? It's only in the first but four days. yeah But let me just add. it's So in the first four days, don't use it.
Speaker: But on the fifth day, you have to use it. This is not optional. we don't The days are just sending anti-PF4 tests. And SRAs without a 4T score needs to be over. The standard of care is first you calculate the 4T score and you look and see what that score is. And then you determine based on that score, whether or not to send the next test starting on day five. yeahp still did and And it's important anywhere between day five to day 30,
Speaker: after cardiac surgery, um calculate the 4T score. And if you see um that combination with a unexpected platelet drop of 30% or more from baseline, or in some cases is a persistently severe thrombocytopenia, or new thrombosis, um that should point you towards a diagnosis. And I do, you know, Dan mentioned earlier about the, you know, the biphasic pattern.
Speaker: It's important to establish what your baseline reference is. So if you say start out preoperatively, you're in the platelet counts in the 300 range, it drops down to say, you know, 100, 110, somewhere there. And then it bounces up to say 140,000. Your reference now,
Speaker: is dynamic, but if you peak at say 140 and then you start to see a drop again, that by basic drop, once you see a 30% drop from 140,000, for example, that would be a tribute, that that's how you can help identify it. So I think sometimes people can can can get very easily get confused on what is the baseline level. Is it the pre-op level? Is it the first post-operative level? That's not the case. The baseline is dynamic. It can move based upon what the platelet count trajectory is.
Speaker: and And that sort of underscores the point why you need to check daily platelet counts because your baseline is can be dynamic. And when appropriate, like you said, incorporate the the four ts scoring to really understand pre-test probability, right?
Speaker: Now, if you have intermediate, high suspicion, you're you're concerned, what's the next step? What's the the the next test? Exactly. So as um I want to so i want back up to one other thing that, um so we can go right into this. So the first um the first test to be able to do is a screening test. And so that would be the HIT immunoassay testing. And so this is most commonly an ELISA, it's an immunoassay to be able to um identify if you have a positive screening test. And so that essentially can kind of help guide um what you need. Now, based upon what you identified, that can help guide your management. So for example, if you um if you see that you've got a patient with a thrombocytopenia, but they have a low probability for ts score, um
Speaker: It is reasonable with a at that point to simply discontinue any heparin that may or may not be going on at that point. So if they're on DVT prophylaxis, for example, um but it is not necessary to go ahead and pursue laboratory testing for HIT, for example, the immunoassay or you know the ELISA test, nor do you need to start any empiric treatment with a non-heparin anticoagulant. That is not recommended. So if you have a low probability 4T score, you're off the pathway, you're done. You can resume back to whatever you were, you know, whatever you were, you were doing. So low being under four.
Speaker: Correct. Three or less. Exactly. Okay, perfect.
Speaker: You know, I think that, sorry, go ahead. No, go ahead, go ahead. I was going to ask you also about the, so obviously that's why it's important, right? Because it saves you an additional test, which like you said, is a screening test that could be a false positive.
Speaker: But of the things that I wanted to ask you is the immunoessay also has degrees, right? Not all immunoessay results are the same. If you could comment on that.
Speaker: Sure. um And so, correct. So there are different, um there are different um you know, in terms of reliability of different tests, most commonly the ELISA is used, um you know, in terms of that. I think where um where this moves into next is if you have a sort of intermediate or sort of high probability, an intermediate test,
Speaker: ah intermediate 4T scores. So let's say you have a greater than four. um um At this point, it is what you should be doing is you should be stopping any heparin and proceeding with a HIT immunoassay test. And that's that's what we, you know, that's what's recommended recommended here. So that's your ELISA test or, you know, your immunoantibody test in terms of that.
Speaker: The immunoassay test has a very good negative predictive value. It's probably on the order. So if you have a low probability 4T score and you, that's nearly a hundred percent, but if you have a intermediate value and then you have a low probability, a low immunoassay score, that's pretty good to be able to successfully rule out hits.
Speaker: and yeah So the number and Eliza OD under 0.4. That's what we're talking about. The P of four Eliza under 0.4 has um, it's very consistent and you're safe now to not pursue anything else. You don't have hit.
Speaker: Rules it out. and And if you need it, you can resume heparin, correct? Correct. It is excluded. Resume heparin. Correct. so we we So we started off with at least an intermediate P4.
Speaker: But mind you, this is after the first four days because we're not sending we're not sending immunoassays in the first four days after cardiac surgery. i want to back the leaders up the the listeners up for a minute. In the first four days after cardiac surgery, we're not doing 4T score and we're not sending these tests.
Speaker: Exactly. and then And then the next point, Sergio, is what I would probably contend maybe the single, one of the single most important recommendations and where the 2026 AATS expert consensus document differs from the 2018 American Society of Hematology guidelines in terms of recommendation of what to do when you have a intermediate probability for T-score. So just to back up for a second.
Speaker: The American Society of Hematology guidelines basically say that if you so order a heparin antibody test, you should do three things. You should um stop any heparin, but you should, and and if you're gonna send the 4T antibody, but you should also start a non-heparin alternative. So typically bivalirudin or Gaproban, something ah along those lines. That is a reasonable recommendation in a medical ICU setting. However, in the immediate perioperative cardiac surgical population, which are, we're talking about day three, four, or five patients who still, you know, are still vulnerable to postoperative bleeding, that can become a problematic aspect because, you know, a lot of, most of our patients typically often will have an intermediate four t score,
Speaker: and then you send a heparin antibody, and then you're waiting for as you're waiting for that result, we're so we're stuck. So what our recommendation is based upon looking at the fact that it's it's quite rare that the prevalence is probably on the order of about 14% of patients who have intermediate HIT scores um to actually have i have a positive antibody test is It's reasonable, in the based upon clinical suspicion, to wait to start any anticoagulation until the immunoassay result is available. So in other words, where the AETS guidelines differ from the American Society of Hematology guidelines, the ASH guidelines say that intermediate 4T, you have to start non-heparin alternative while you're waiting for your immunoassay.
Speaker: The AATS guidelines leave that at the clinician's discretion so that if you send a heparin, if you have an intermediate 4T score and you send a immunoassay result, it is reasonable. It's a two-way recommendation that it's reasonable to wait to start a non-heparin anticoagulant until the immunoassay result is available. Okay.
Speaker: Excellent. And I'll ask, I mean, and since we're on the topic, if I had a high 4Ts, would my therapeutic conduct around the anticoagulation be different?
Speaker: Yes, it would. Yes, you would start a non-heparin anticoagulant if you have a high 4Ts. Or I thought it was the question you were going to ask, if you had a high obstacle density on your PF4, a high OD, that means over 1.0,
Speaker: you should start a non-heparin anticoagulant while you are you know treating this patient who most likely has it. new you're waiting The thing you're going to do after that is a functional assay. We still don't know for sure, but it's more likely than the 14% that Shuba was describing for all comers.
Speaker: Perfect. Exactly. And and that this is, again, ah what I want to be clear. It does not mean to say that you don't have to start a non-heparant alternative in this setting. It gives the clinician at the bedside the um the clinical picture to be able to make a decision if anticoagulation, is it reasonable to wait or do they is it ah you know worth starting? And I think I would say, Sergio, in general, patients who have a high 4T score um almost always have some evidence of thrombosis. So in that setting, you know if you see thrombosis, it doesn't matter what your 4T calculates out, it doesn't matter what your immunoassay result is, if you see thrombosis, you should start anticoagulation until you get your... with thrombocytopenia.
Speaker: Yes. Thrombosis with thrombocytopenia. That's what we're talking about. Yeah. Specifically, because by definition, you're going to get two points for the thrombosis. You're to two points for the thrombocytopenia, and you're going to get a point or two from the heparin exposure because of the cardiac surgery. So you're already a high. That's what Dr. Chatterjee is kind of getting at is the four Ts. If you spend the time figuring out is going to be high, it'll be, uh, you know,
Speaker: six at least. And backing up to what Dan was ah pointing out before, you know, so many times in an ICU setting, it's very easy on day three two, day three, even up to day four to see thrombocytopenia and to just say, oh, well, just like just send a heparin antibody, you know, just kind of a drive-by, just, you know, like yeah sometimes you'll say, you know, the When when you mentioned thrombocytopenia, the first thing that comes to mind is send the antibody. We used to, you know, many people think that's just a benign thing. So I would say, i would caution in two respects. One is if you send the heparin antibody test,
Speaker: According to the American Society of Hematology guidelines, if you sent that antibody test off and like it came back negative you know and you didn't do anything else, you kind of no harm, no foul.
Speaker: However, if you sent to antibody, but in the meantime, you either kept your DVT prophylaxis going or you didn't start a non-heparin alternative, while you waited 24, sometimes 48 hours for your immunoassay test to come back,
Speaker: If it came back positive, now you just went a period of time from the time you sent the heparin antibody to the time the diagnosis came back or or the the result came back and you started anticoagulation. Technically, according to the previous guidelines, you would be subject to faults because why didn't you start your non-heparin alternative at the time of the um time you sent the heparin antibody off? So I want to clarify. So in the past, that practice of sort of drive-by sending a heparin antibody off without starting a non-heparin alternative, you know, exposed surgeons, intensivists to medical legal exposure.
Speaker: But let's be pragmatic. We're not all at a giant medical center, and these heparin antibodies, can take three or four days to come back sometimes If we happen to try to send one on a Friday afternoon, there's zero chance I'm getting it back until late Monday or Tuesday. So that's four days now of trying to figure this out without an antibody test. It's not easy. This hit stuff is difficult. There's a lot of judgment that needs to go into it.
Speaker: And like as you mentioned earlier, right, every clinical decision has to weight benefits and risk. In medical patients, well the risk of bleeding is lower than the risk of thrombosis. Exactly. In a surgical patient, the other way around. I've to tell you, a fresh post-op cardiac surgical patient,
Speaker: The cardiac surgeons are not comfortable starting, you know, bivalrudin on just willy-nilly. It is not benign. it isn't It is a big deal. So we will not just throw this stuff around because patients do bleed, and there's a significant portion of the patients that bleed in the early post-operative timeframe when you're starting non-hyperinanic coagulants. Yep, I think that's an important distinction.
Speaker: They're not reversible. yeah The one thing I wanted to ask you in the in the post-op day number one to four, um it seems that based on how I interpret and and read the document also, that documented previous exposure in the five to 10 day range or any suspicion or evidence of thrombosis would make me maybe think a little bit different. Is that is that true? Yeah.
Speaker: Definitely the thrombosis. And patients who come in with ACS, Q-carnary syndrome, or they're sitting with a balloon pump, and they're on heparin for a few days before cardiac surgery, then they have the cardiac surgery, and then their platelet counts plummet.
Speaker: and stay low, you have to be thinking about hits. You just have to. it's it's it's It's out there. That said, these are also the patients at highest risk for bleeding. So starting a non-heparin anticoagulant without any proof of the positive antibody is hazardous in and of itself. So this is not a perfect answer yet.
Speaker: Shuba? ah What I would add, I think that's a really good point, Tane. I would add, you know, on day two, remember, not all thrombosis is necessarily hit. It's possible. But, you know, there are other causes of thrombosis on day one, day two, say, you know, previous lines or something like that. So you do have to be suspicious just in terms of that. But I agree with it.
Speaker: i agree as well. Excellent. Can we talk about the step four or last step, the confirmatory test, which is the functional assay? So we we kind of discussed when you should be ordering this. So if you get to a an immunoassay that's intermediate or ah that's high, you probably would go at that point for the functional assay, which I understand is a confirmatory test. Can you tell tell us a little bit more about that?
Speaker: Exactly. So um if you have a positive immunoassay, confirmatory testing with a functional assay is recommended, and that's a class one recommendation. And that is why, that is because, as Dan mentioned at the beginning, somewhere between 30 to 50% of patients will develop heparin antibodies immediately after cardiopulmonary bypass. The question is not, do they have antibodies? The question is, are those antibodies functional and actually acting? That further underscores why you shouldn't just sort of like kind of you know like do the order, a antibody, unless it's in and indicated.
Speaker: um But the the pathogenic anti-PF4 heparin antibodies, um what you're really looking for is the serotonin release assay. That has a very high sensitivity and specificity for it and is considered the diagnostic gold standard.
Speaker: And when that comes back negative, if it does, you can start heparin. We're done. You don't have hits. That's it. Game over. That's an important thing. That your functional is real.
Speaker: yeah Right. And I think that there are, um you know, one of the things that can happen, Sergio, is that once, um and this is, you know, once you can, um once a patient has a positive immunoassay, so the antibody test is positive, what some people will do is they will go ahead and put in their ah medical record that now they have a heparin allergy. But if the um if the ah the serotonin release assay comes back negative, it's really mandatory to be able to make sure that there's no persistence in the ah ah the medical record. that there actually is a heparin allergy because it will, these things can perpetuate, you know, there was one study where something like it took like five or seven years before somebody actually just appropriately took the false medical allergy to heparin. off of that. So I think it's important to um be deliberate that if the ah SRA test is negative to make sure that, you know, there's no evidence of of that because it ah it means you don't have it. And it also means that if you actually see somebody on their medical record that they have a heparin allergy, it's important to document what that was, what that was based on, and and really confirm that that's either a true heparin allergy or that was just sort false documentation.
Speaker: Excellent. and the the test And the other question I had is once you confirm that somebody has HIT positive by the function assay, what other tests should the clinician order?
Speaker: So if you… a Go ahead, Dave. Yes, sure. No, I would say that. So it is. So the first thing you need to make sure of is that and hopefully you've already done this, but you need to confirm that you are therapeutically anticoagulated. So it is. um And most of the time that this occurs, um you know, you can see it in really two settings when we see it.
Speaker: in patients who have confirmed HIT, who are at increased risk of bleeding, or you know they're going to have additional invasive procedures, or they're in the ICU. um An IV direct thrombin inhibitor, such as bivalirudin or Gatroban, is probably, are either of them are appropriate because of their short half-life.
Speaker: It's different when they are confirmed, yet say they come in on the floor or say, for example, they come they go home and they come back and they present with that. Then you have different oral alternatives you can go with, or Afonda Paranox, Dynaperoid, or direct oral anticoagulants, either of those may be appropriate. um I think going to what you should also look for is it is also reasonable to, and what you should do, is a surveillance forelimb Doppler ultrasonography to look to see if there is presence of any other thrombo-occlusive disease. That may influence the duration of anacogulation for your patient subsequently.
Speaker: If I could talk about the the ultrasound. So historically, and I'm guilty of this also, with suspected hit, sometimes we would get a four limb ultrasound surveillance thinking we were helping the situation. It turns out we were not helping the situation. And why is that? Because a significant patient population has had a central line and has a clot there at the site of central line insertion. And all our patients have a central line in cardiac surgery. So we're finding these unrelated clocks in a patient with suspected hit.
Speaker: And now that moved that patient up in our 4T score and our worry about hits. And now we're thinking, well, we really have to start this non-heparin anticoagulant. When in point of fact, you should really only do the four limb surveillance ultrasound in patients with confirmed hit for the exact reason that Dr. Chatterjee pointed out. It's to determine the length of therapy for confirmed hit.
Speaker: Perfect. We talked about it. Go ahead, Shubha. I was going to say, Sergio, then i was going to transition into, you know, now that you've treated, how to sort of move forward. So typically in, um you know um you know, I would say most commonly we've used vitamin K antagonists, so warfarin, you know, in the United States and North America most commonly. So um typically when that should be started is um once platelet count recovery has occurred. So that is typically greater than 150,000 in terms of when it's appropriate to start warfarin. And that has to do with ah you know, depletion of protein C and and and and S in terms of, you know, when to start things. i I would reinforce that, Shuba, because that's a big point. That's really important. Do not start.
Speaker: warfarin until the platelets are above 150, because a lot of times it takes forever to get those platelets to recover and you're just desperate to start that warfarin. You're thinking, well, we're fine. We're on a non-heparin anticoagulant. Let's just get the Coumadin in there so we can get this patient out of the hospital. But you can't do it because of the pro-coagulant properties.
Speaker: um That does not necessarily apply if you are transitioning to, say, direct oral anticoagulant in terms of the same. Again, the 150,000 has to do to the Warfarin protein, CNS, in terms of that. But if you want to start a DOAC earlier, um that that's reasonable you know if you're at that appropriate stage. You know, I think one of the other questions that pops up is, um okay, well, the platelet count is 50, 40, 30.
Speaker: Should I give them platelets? So you really want to do your best to avoid giving platelets um for patients ah who do have hits.
Speaker: um ah That should be avoided at a certain point. um Now, that said, if you have a patient who's bleeding um and they have low platelets, you need to the bleeding comes first. And so you need to address the platelets. But just empiric, there's a low platelet count. I want to give platelets. You should avoid that. There's no really good evidence on when to you know when to empirically give platelets just because the platelets are low. I would say that probably the hematology, some of the you know blood you know diseases, they probably would recommend empiric transfusion somewhere between
Speaker: 10 to 20,000 to avoid CNS bleeding. We don't have any good data to say when is it, quote, safer or not safe. we We would say like the general guideline management would be appropriate in that setting. But by and large, I would avoid giving platelets or we should you would avoid giving platelets empirically just for the sake of, you know, unless it's a severely low count.
Speaker: In the ICU, when they're critically ill or when we're taking care of them ah in the ICU, youre like you said, you're probably going to be dealing with direct trauma inhibitors. Could you mention the advantages of one versus the other? How do you decide? Is that dependent on the patient, on the expertise of the team, or how do you think about it?
Speaker: So um great question. There's no head to head. There's not really any good bivalorudin versus argatroban head to head comparison there. um You know, bivalorudin is has a renal metabolism and argatroban is hepatically cleared. So there may be an argument in you know, based upon that to adjust it. I will say this is highly institutionally dependent, um you know, in terms of it personally. at our own center, we too you know I think we've used bivalorudin much more ubiquitously in our ECMO population. And so based on that familiarity and and and dosing, our familiarity and comfort with dosing bivalorudin, we tend to do bivalorudin regardless of renal function and just adjust accordingly. But there's no real good data there. Dan, what what do you what do you do in that?
Speaker: Springfield. We do the same. It it seems my sense is across North America is that the cardiologists got much more comfortable with bival in the cath lab, and that's why it's moved its way into intensive care. unit And it also seems as though the price must have come down because I used to get tons of pharmacy pushback, and now they seem to be accepting it. And I also like the fact that the half-life is a little bit lower with bival than it is.
Speaker: With our gachaban, not much, maybe, I don't know, it's like 25 minutes versus 50 for our gachaban, but, you know, we'll take that. What about refractory HIT? So we start one of the direct thrombin inhibitors and we're just not seeing any recovery in the platelets.
Speaker: um but ah that That can be a tough, that's ah that's a difficult problem. And so typically in that setting, if we don't see recovery, um you know, we need to try to clear the antibodies. And so there are, um you know, those strategies include IVIG, intravenous immunoglobulin,
Speaker: or therapeutic plasma exchange, both of which may be considered in sort of these refractory cases. um Not really great data in terms of head-to-head comparisons of one versus another to indicate that one is necessarily better than the other, but typically, you know, the appropriate strategy would be you know, um you know, and and a lot of that is sort of institutionally dependent. And we can get into it even a little bit more when talk about the patient who has cardiac surgery, who needs cardiac surgery, but those would be sort of the general strategies.
Speaker: Before we go to that topic, one last question on treatment is how long should you anticoagulate these patients?
Speaker: Excellent, so it depends a little bit on the clinical setting. So if you have, um I'll take the you know the patient who has heparin-induced thrombocytopenia, but fortunately is relatively spared from thrombosis. So for in that patient, it can range. It can be as short as just platelet recovery, which could be you know a couple of weeks,
Speaker: or it could be up to three months. So in the patient who um has hit but doesn't have thrombosis, um you typically somewhere between a few weeks to up to three months would be reasonable. Now, it differs, however, if that patient um developed thrombosis. If a patient developed thrombosis, that mandates somewhere between a three to six month course of anticoagulation and probably not compelling data on three versus six months. I think it depends a little bit on the other co you know comorbidities, other thromboembolic risk factors, the extent of the um clot burden, but typically somewhere along those lines.
Speaker: Let's talk about the patient who has a history of HIT and now needs cardiac surgery. Dan, and I guess you would probably think about this in terms of emergent versus non-emergent surgery, but how do you handle this?
Speaker: start with sending an um immunoassay, and you have to know whether there are actually antibodies still present before you plan anything. um Historically, programs all did this differently. There was no standardization and it was kind of a mess based on the local habits and hematologists. So if this immunoassay is negative or positive with a negative functional assay, just proceed and use intraoperative heparin. That's a big deal.
Speaker: So negative immunoassay or positive with a negative functional assay, you're done. Intraoperative heparin, done. And the risk of recurrence with this brief intraoperative unfractionated heparin, the amount we give at the the operating room is very low.
Speaker: So I'm not particularly worried they're going to get hits again. In those cases, do you do anything special in the post-op period in terms of follow-up? and Same thing, just daily play with counts and you're done because we know ah that patients with a prior history of hit and negative assays, there's minimal to almost no recurrence of thrombosis, assuming the heparin was just restricted to the operating room. So don't give them, you know, post-op daily sub-q heparin for DVT prophylaxis, just one shot in the OR and done.
Speaker: Perfect. Now, the next one is the confirmed hit with a positive functional assay. So the first thing you got to do is delay non-emergent surgery. Just wait, give it time. Because with enough time, you can usually get the functional assay negative.
Speaker: The antibodies usually only persist for two to three months. So if you can wait, it's non-emergent, you should wait.
Speaker: And the last category, which and when it's emergent,
Speaker: and have a positive functional asset. Now you got a problem. ah You can use bival. Some centers are able to use bival alone on cardiopulmonary bypass. It's difficult. You get a lot of bleeding. You can't reverse it. You got to sit around on the operating room and wait.
Speaker: But centers have done it, and there are protocols set up at many centers to do it, including my own. Or you can use heparin, restricted to cardiopulmonary bypass, but then you use what we call antibody-modifying adjuncts, such as preoperative IVIG and you know plasma exchange.
Speaker: So clearly not a fun day for the surgeon.
Speaker: That's a good summary. Yes. yeah It's not a fun day surgeon, but profusionists are involved with this. They have protocols set up. As long as you, you need to be ready for this because you're going to eventually have that patient with, you know, hits or a function functional positive assay hits who need surgery. They're having chest pain. They have a bloom bump in and you're going have to move ahead. so those are your two choices.
Speaker: And I think I would add that I don't think there's a there's um you know, you can try plasma exchange for a few days and then a dose of IVIG and then you go. There are multiple different ah protocols that have ah sort of been reported.
Speaker: you know, there's no clear, you know, evidence that one is necessarily better than the other. It's ah try try the strategies and kind of hope and pray. And I think it's. Yeah. Go ahead. go so but go ahead Sergio, for your audience, this is the weakest evidence corner of this entire document. I mean, we are really pushing the limit. There's very little data here. We're at a 2B recommendation.
Speaker: ah And, you know, the panel was explicit that this remains a research priority. So I would not put too much time into this area with so little data to back it up.
Speaker: Perfect. Understood. And also just to, I think it reinforces the point, Suba, you made earlier that being very thoughtful about how we document things is critical, right? We don't want to expose people to the wrong treatments or challenges because we didn't do the right test and we didn't remove a non-existent allergy when it was negative at the time. So all this has a lot of implications for our patients.
Speaker: Absolutely. i mean, you can imagine, you know, you know, embarking on, ah you know, an extensive workup or delaying something that that shouldn't have been delayed, you know, so it's it behooves us to, you know, examine that and be deliberate about who we designate as having or not having a hepatitis allergy.
Speaker: you know You know, one more thing we didn't really touch on is we need to put pressure on our hospital systems to have more rapid turnover of of especially the PF4 immunoassay. Because if you're sending this thing out and you're making your clinicians wait a week for the result, it's really going to tie our hands behind our back and make it very difficult to treat these patients in an expedited, safe fashion.
Speaker: agree and very time sensitive and something that our clinicians should be talking with our hospitals and and pushing for if they have that long turnaround. Shuba, can we talk about ECMO and MCS becoming more and more common in many, many centers around the country? Obviously, big explosion with with with with with a heart failure population.
Speaker: What are the specific recommendations for this population around HIT? So, um you know, unfortunately, with ECMO and other MCS, heparin-induced phombocytopenia can occur up to 10% in 10% of cases. So um you have to have a high degree of vigilance and you have to be very deliberate about looking for it.
Speaker: Unfortunately, in the um ECMO setting, and this is not just within the first four days, this is any time during ECMO, the 4T score is just notoriously unreliable. We're talking about you know on the order of like about a thirty you know less than 30% positive predictive value. So our recommendation is just ignore the four t score.
Speaker: um you are looking for thrombocytopenia, you're looking for thrombosis and being very deliberate. And if you have that, then sending the heparin antibody. um ECMO is different. When you have somebody on ECMO, unlike the standard hit patients, suspected hit patient, post-cardiac surgery, who is not on a systemic anticoagulant, if you have somebody on ECMO,
Speaker: um and whom you suspect may have hit, you should just right away switch to a non-heparin alternative and send out a heparin and send your heparin antibody test to confirm whether or not that patient does indeed have hit or not.
Speaker: And I think as we close, I would love to hear and a summary of the take-home points. And Dan, maybe you could help us with this. Sure. um Well, let's make them quick. Number one, new thrombosis considered hit.
Speaker: That's it. you You just got to go consider it. It has to be on your differential. Think about it. and Any new clot after cardiac surgery is hit until proven otherwise at any post-op day, not just day five or on, but there's so much heparin exposure pre-op. It takes five days to make the antibody, but if they got heparin pre-op, that could be any post-op day. My next one would be early post-cardiopolar bypass. Platelet drop is normal to 40% to 50%.
Speaker: Fall is normal, but the nadir, the bottom of that should be day two, three. That's usually not hit, and it should start to then recover after two to three days. A second play with fall beginning on or after day five, classic hit pattern by Fasic.
Speaker: The baseline is the highest post-operative count, as Shubal was mentioning. Four T-score unreliable in the first four days of cardiopulmonary bypass. So don't use it. Just don't waste your time calculating it. Use the other stuff.
Speaker: Think about new thrombosis. You've got to do something and watch the platelet trends and look for that recovery after two to three days. And we just talked about how the 4T score unreliable du in ECMO, who's a very poor predictive value.
Speaker: So forget that. A positive immunoassay is not hit. So we need to confirm with that functional assay because half the patients will seroconvert. Think about that. That's something I didn't know before we wrote this document, that half the patients will have a positive PF4 and it's still not functional.
Speaker: and um I would add here... Yeah. At this point, um you should be um if you just have an intermediate 4T score, so you're looking at an intermediate score of, say, 4 or 5, and your immunoassay is weakly positive, so less than 0.4, or you're still waiting for the immunoassay, you do not have to empirically anticoagulate. Again, this is where this guy this expert consensus document differs from the ASH guidelines. You should be thoughtful and you should be deliberate. If you are just if you just sent an immunoassay because of thrombocytopenia and there's a biphasic pattern, it's intermediate, you're looking for it. You don't see obvious thrombosis.
Speaker: It's reasonable to wait. until you until a confirmatory test. um Try not to routinely transfuse platelets because it does increase the thrombosis risk. So unless the platelet count falls to very, very low levels, avoid just the routine impaired platelet transfusions. um How long do you treat after you develop HIT? That varies. um no you know Six weeks to three months in the setting of just HIT, three to six months in the setting of HIT with thrombosis. And then finally, if you have confirmed preoperative HIT, that is conformatory test, confirmed um and you have urgent surgery and you can't wait it out, then either use bivalurudin or go with a plasma exchange IVIG, unfractionated heparin. At the time, most centers um have some sort of, have thought through this, obviously with hematology consultation. And the last thing I think, just to put all of this is you suspicious look for thrombosis um and be mindful of it and and and keep track of what your platelet count does um you know in your medical record system to be able to get to keep an eye on looking at it. And finally, be aware of those patients who received heparin prior to surgery. They may present a little bit earlier. So just be mindful of that.
Speaker: Excellent. We'd like to finish the podcast with a couple of questions that are unrelated to the clinical topic. Would that be okay? Sure. Absolutely. So I'll go and with Dan first.
Speaker: Is there a book that has influenced you significantly or that you have gifted often to other people?
Speaker: There's not a book I've gifted to a lot of people, but the last book I read kind of, ah stuck with me. it was um It was this true story of ah husband wife who were stuck floating at sea for three months, called Marriage at Sea. And what it really pointed out to me is the ah power of the human mind and human will to survive, which we see that every day, shuba and I in the intensive care unit, and that if people have a a strong enough will to live, they can overcome unbelievable obstacles.
Speaker: Excellent. Shuba, what about yourself? What book would you would you bring to to our audience? So I would ah credit my fellow co-panelists. So Dr. Daniel Engelman, probably maybe a little less than 10 years ago, um thought that he he could, has dedicated his mission to improving perioperative care in cardiac surgical patients. So he is the president and founder of the ERAS or Enhanced Recovery After Surgery Cardiac Society. So ERAS Cardiac. I being joined Dan on the executive board ah in 2019. And so ERAS Cardiac is designed to perfect the surgical journey to get patients to be able to recover faster. For those who are interested, it's at erescardiac.com. And Dan... No, it's.org.
Speaker: Sorry,.org. erescardiac.org. But Dan and his colleague at Bay State, Cheryl Krasafi, wrote a book called ah Perfecting the Surgical Journey. It's directed to... Cardiac Surgery Playbook.
Speaker: There you go, Cardiac Surgery Playbook, um which is dedicated to patients to explain ah what they should experience, what's normal, to take the anxiety out of the cardiac surgery process. And it's a delightful book to be able to explain the why and the what to get patients to recover faster.
Speaker: Excellent. And we'll make sure that we have a proper links to the books, but also to and the heiress and cardiac society. So we'll, we'll make sure of that.
Speaker: The next question then for you is tell us something you changed your mind about in the last few years. Hmm. Uh, well, let me think about that. Um, so what i didn't really realize What I didn't realize is that there was effectively no standard of care for perioperative cardiac surgery that differed from other aspects of surgery. And that um a lot of the things we do in our intensive care unit were just based on sort of how our
Speaker: predecessors did things without a lot of data, without a lot of precedent. And it turns out there's a ton of evidence-based best practice that really should frame what we do every day in cardiac surgery. And I'm talking about everything, fluid resuscitation, when to extubate a patient, how to treat their pain, when you can mobilize safely, how you can mobilize everything about our perioperative journey. It turns out there there has been a lot published and we're not standardizing it in our intensive care units. And and there's sort of a a lot of room for us to improve is basically what I've learned.
Speaker: Excellent. And Shuba, last question for you is, what would you want every listener to know? It could be a quote or a final thought.
Speaker: um I would say that To be involved in ah healthcare care and medicine is a privilege and we owe it to our patients to try to get 1% every day. Because if you can get 1% better every day, meaningful improvement and change can occur. And so that's just it. I think we owe it to our to our patients and ultimately to ourselves and the next generation to just try to get 1% better every day.
Speaker: Excellent. And gentlemen, I just want to thank you for a wonderful discussion. I've definitely learned a lot reading the document, but also talking with both of you today. want to thank you for your efforts and moving forward. Obviously, this is very complicated topic that impacts our practice.
Speaker: And as you mentioned, it might be less common than it shows up in our discussions, but doing the right thing and having an organized approach can really make a difference for our patients.
Speaker: Look forward to seeing you back on the podcast soon. And thank you for your time and expertise. Thanks very much, Sergio. Thank you, Sergio. Thank you for listening to Critical Matters, a sound podcast.
Speaker: Make sure to subscribe to Critical Matters on Apple or Google Podcasts and share with your network. Sound's transforming the way critical care is provided in hospitals across the country.
Speaker: To learn more, visit www.soundphysicians.com.


